NCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
12 trialsNCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT02807181 2025-05-09
SIRCCA
Sirtex Medical
Phase 2/3 Terminated
NCT06355427 2025-04-11
FAPIChol
Erasmus Medical Center
Phase 2/3 Recruiting
NCT06923475 2025-04-11
NEODISCO
Amsterdam UMC, location VUmc
Phase 2/3 Not yet recruiting
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT03086993 2022-03-24
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2/3 Unknown
NCT02108145 2019-08-01
Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
Air Force Military Medical University, China
Phase 2/3 Unknown
NCT02482454 2017-08-01
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
The First People's Hospital of Changzhou
Phase 2/3 Active not recruiting
NCT01755013 2017-02-20
Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Weill Medical College of Cornell University
Phase 2/3 Unknown
NCT01739465 2013-02-26
Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma
Guangzhou Medical University
Phase 2/3 Unknown